Mitra D, Darden C, McSorley D, Davis K, Band J, Iyer S. Patient reported treatment satisfaction with palbociclib combination therapies for HR+/HER2– advanced or metastatic breast cancer in multiple countries. Poster presented at the ISPOR 23rd Annual International Meeting; May 22, 2018. Baltimore, MD.


OBJECTIVES: To understand patient reported treatment satisfaction with palbociclib combination therapies in HR+/HER2‒ advanced/metastatic breast cancer.

METHODS: A web-based survey was conducted in the United States (n=250), Canada (n=100), and Germany (n=100). Respondents were ≥18 years old and had received palbociclib plus aromatase inhibitors (AIs) or palbociclib plus fulvestrant for ≥2 months. The Cancer Treatment Satisfaction Questionnaire (CTSQ) was used to measure satisfaction. The CTSQ has three domains: expectations of therapy in preventing recurrence or progression or returning to normal life, feelings about side effects, and satisfaction with therapy. Each domain is scored from 0-100, with a higher score indicating better outcomes. Descriptive statistics are reported for the overall cohort and by country.

RESULTS: The majority of respondents were Caucasian (84.2%) and were employed (54.2%). Median age was 40 years. Approximately 43% (n=194) of the study population had received palbociclib plus AI. Average (SD) satisfaction with therapy scores were 71.6 (10.9) for the overall cohort, with patients in the US reporting the highest score of 73.2 (11.6). Average (SD) expectations of therapy scores overall were 73.4 (14.5), with the scores being highest for patients in Germany at 75.8 (10.2). Overall, most patients (79%) reported that they felt palbociclib would help them return to a normal life and over 90% of patients reported that the benefits of their palbociclib combination therapy met or exceeded their expectations. Average (SD) scores for feelings about side effects were 44.7 (13.8), with Germany reporting slightly higher scores (45.3 [11.8]). Similarly, more than 90% of patients indicated that if given the choice they would take palbociclib combination therapy again (range 90% in Canada to 97% in Germany).

CONCLUSIONS: Patients reported high satisfaction scores with palbociclib combination therapy in all three countries, with Germany reporting slightly higher scores for expectations of therapy and feelings about side effects.

Share on: